(Q84579133)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20643092%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

title

Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20643092%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

author name string

N De Carvalho

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20643092%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

J Teixeira

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20643092%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

C M Roteli-Martins

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20643092%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

P Naud

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20643092%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

P De Borba

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20643092%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

T Zahaf

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20643092%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

N Sanchez

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20643092%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

A Schuind

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20643092%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

publication date

17 July 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20643092%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20643092%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20643092%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

issue

38

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20643092%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

page(s)

6247-6255

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20643092%20AND%20SRC:MED&resulttype=core&format=json

Global cancer statistics, 2002

8 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.007

Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.007

Higher prevalence of human papillomavirus infection in migrant women from Latin America in Spain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.007

Burden and trends of type-specific human papillomavirus infections and related diseases in the latin america and Caribbean region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.007

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.007

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.007

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.007

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.007

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.007

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.007

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.007

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.007

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.007

Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.007

Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.007

Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.007

Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vacc

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.007

Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.007

The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.007

Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.007

Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.007

A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.007

Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.007

The causal relation between human papillomavirus and cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.007

Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.007

Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.007

Against which human papillomavirus types shall we vaccinate and screen? The international perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.007

10.1016/J.VACCINE.2010.07.007

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20643092%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference